The NDA of Grand Pharma’s Global Innovative RDC TLX591-CDx Is Accepted by the NMPA
R&D Centers
R&D People
Projects in Progress
The NDA of Grand Pharma’s Global Innovative RDC TLX591-CDx Is Accepted by the NMPA
Grand Pharma 2025 Annual Highlights Review
Grand Pharma’s Subsidiary Has Entered Into a Share Purchase Agreement to Acquire All Equity of Hebei Yuanda Jiufu Biotechnology Co., Ltd. and Baoding Jiahe Fine Chemical Co., Ltd.
PHARMACEUTICAL TECHNOLOGY
NUCLEAR MEDICINE ANTI-TUMOR DIAGNOSIS AND TREATMENT AS WELL AS CEREBRO- CARDIOVASCULAR PRECISION INTERVENTIONAL DIAGNOSIS AND TREATMENT TECHNOLOGY
BIOTECHNOLOGY